RegenMed

WHITE PAPER

ACCELERATING CLINICAL, RESEARCH, AND FINANCIAL INNOVATION IN CF CARE

April 30, 2025

RegenMed

TABLE OF CONTENTS

SUMMARY

Cystic fibrosis (CF) is a model of medical progress, transforming over the past few decades from a fatal childhood illness into a manageable chronic disease for many patients. Breakthrough therapies – most notably CFTR modulators – have dramatically improved outcomes [3,4]. Today, the median predicted survival for people with CF has climbed into the 50s (years of age), up from the 30s just a decade ago, thanks to advances in multidisciplinary care and disease-modifying treatments [5]. Patients are living longer, healthier lives, and new challenges and opportunities are emerging as a result. Key issues now include managing long-term comorbidities of CF, reaching the remaining patients who lack effective modulator options, and continually adapting care models to sustain improvements in quality of life. The evolution of CF care, from aggressive nutritional and antibiotic regimens to precision medicines targeting the CFTR protein, showcases the power of innovation. Yet this rapid progress also highlights a critical need: real-world data and collaboration to ensure every patient benefits fully from these advances [6,7].

Despite the successes, many CF centers still struggle to measure outcomes, track long-term success, or collaborate with peers in real-time[7]. Even in this data-rich field (bolstered by efforts like the CF Foundation Patient Registry) [1], individual clinics often lack infrastructure to harness data for day-to-day decision making. Questions abound: How are different patient subgroups responding to modulators over years? Can we safely reduce traditional therapies in the modulator era without compromising outcomes? What best practices distinguish the highest-performing CF programs? These are questions no single clinic can answer alone. There is a growing recognition that longitudinal real-world evidence (RWE) is essential — not optional – for tackling such questions and continuing to drive improvements in CF care and research [8,9].

RegenMed Circles for CF is a new approach designed to close this gap by giving CF clinicians and researchers powerful tools to collect and leverage real-world data from everyday clinical practice [10]. Circles are secure, physician-led data communities that make it easy to capture structured, standardized, and compliant real-world data (RWD) during routine CF care. Participants can seamlessly track key outcomes (lung function trends, exacerbation rates, nutritional status, etc.) across their patient population with zero disruption to workflow. The platform then enables centers to compare de-identified outcomes with regional or national benchmarks and collaborate with peers on treatment innovations in real-time. The result? Better insights, data-driven protocols, and enhanced patient outcomes – across the entire CF community.
While revenue potential through data licensing is a compelling feature, the primary mission of RegenMed Circles is to create collaborative clinical networks focused on accelerating treatment advances and clinical excellence in cystic fibrosis. By participating in a CF Circle, care teams not only improve their own patient care with data, but also gain access to rich benchmarking dashboards, multicenter peer collaboration, and opportunities for scientific and professional growth. Centers can contribute to cutting-edge research (and even regulatory science) by sharing de-identified data, all while maintaining full ownership and control of their patient information. In short, RegenMed Circles for CF aligns clinical, research, and business value: empowering clinicians to deliver better care today, drive innovation for tomorrow, and unlock new revenue streams through the responsible use of real-world data.

CLINICAL BACKGROUND OF CYSTIC FIBROSIS

Cystic fibrosis is a life-limiting genetic disease affecting approximately 30,000 patients in the U.S. and 70,000 worldwide [2]. It is caused by mutations in the CFTR gene, leading to dysfunctional CFTR protein channels. The result is thick, sticky mucus in multiple organs, most critically the lungs and pancreas. Clinically, CF is characterized by chronic lung infections, progressive respiratory decline, pancreatic insufficiency with malabsorption, and a host of complications affecting nearly every organ system [2]. For decades, standard CF management focused on treating symptoms and complications: aggressive airway clearance therapy, inhaled medications (such as antibiotics and mucus-thinning agents), pancreatic enzyme replacement, nutritional support, and ultimately lung transplantation for end-stage lung disease. This comprehensive care model, delivered via specialized CF care centers, steadily pushed median survival from childhood into young adulthood by the early 2000s [5].

Therapeutic evolution in CF has accelerated in the past ten years with the advent of CFTR modulator drugs, which target the basic defect in CFTR protein processing and function [3]. Early modulators like ivacaftor (approved 2012) showed that improving CFTR function in certain mutations could lead to dramatic gains in lung function and weight, essentially changing the disease trajectory for the first time [3]. Ivacaftor, however, benefited only a small fraction (~4%) of CF patients with specific gating mutations. Since then, combination modulators were developed to address the most common mutation (F508del) and others: lumacaftor/ivacaftor and tezacaftor/ivacaftor expanded treatment to more patients, and finally the triple therapy elexacaftor/tezacaftor/ivacaftor (brand name Trikafta) was approved in 2019 [4]. Trikafta proved to be a game-changer, eligible for roughly 90% of people with CF (anyone with at least one copy of F508del). Clinical trials and early real-world experience with Trikafta have shown unprecedented improvements: average increases of 10-14% in FEV_1 (lung function), reductions in pulmonary exacerbations and hospitalizations, weight gain and improved BMI, and marked improvements in patient-reported quality of life [4,6]. The availability of these highly effective modulator therapies (HEMT) means that for the vast majority of CF patients, the disease can be managed at its root cause, greatly prolonging life expectancy and altering the course of CF care [5,6].

With patients living longer and healthier, the CF patient population's needs are evolving. Younger children are now being started on modulators in early life, which could prevent or significantly delay disease manifestations – but their long-term outcomes remain to be seen [5]. Adults with CF are experiencing fewer respiratory symptoms, but now encounter new challenges: for example, previously rare comorbidities like CF-related diabetes, liver disease, and osteoporosis are now more common as patients age [2,6]. Paradoxically, issues like overweight and metabolic syndrome are emerging (where historically undernutrition was the norm) due to better health and modulator side effects (e.g. increased appetite and weight) [6]. Women with CF are having successful pregnancies in greater numbers, raising questions about pregnancy management on modulators [5]. Meanwhile, a subset of patients (approximately 5–10%) still do not have modulator treatments available due to their particular CFTR mutations or contraindications [3,4].

For them, as well as for those with advanced disease, the focus remains on lung transplantation, novel genetic therapies in development, or inclusion in trials for next-generation treatments [7]. In summary, CF care today is a complex interplay of managing a chronic, multi-system condition with both traditional therapies and revolutionary new drugs. It demands continuous adaptation: clinicians must balance therapy burden (e.g. should a patient on Trikafta continue all their nebulizers and physiotherapy?), monitor for emerging health issues, and ensure that no patient is left behind as new therapies roll out [6,7].

This dynamic landscape underscores the need for robust data and evidence to guide care. How do we optimize therapy combinations in the modulator era? How do we identify patients who aren't responding as expected and intervene early? The answers lie in the careful collection and analysis of long-term, real-world clinical data from CF centers around the globe [7,10]. The CF community has a strong foundation in this regard – most notably the CF Foundation Patient Registry, which has tracked outcomes for decades and contributed to many care improvements [1]. However, as treatments become increasingly individualized and novel questions arise, there is a growing need for more agile, collaborative, and granular data tools that operate in real-time at the point of care. This is where RegenMed Circles for CF enters the picture as a natural next step in the evolution of CF care and research [10].

LIMITATIONS OF CURRENT CARE MODELS

The traditional CF care model – centered on accredited CF care centers with multidisciplinary teams – has been highly successful [2]. Regular quarterly clinic visits, proactive treatments, and standardized protocols have improved survival and quality of life. However, even this gold-standard care model faces limitations in 2025, especially when it comes to data utilization and coordinated innovation:

Siloed Data and Outcomes Tracking

Clinics collect a wealth of patient data (pulmonary function tests, infection cultures, treatment regimens, etc.), but often lack systems to aggregate and analyze these outcomes systematically [6]. Important metrics may be tracked informally or not at all outside of annual registry reporting. For instance, a center might not continuously evaluate its own rate of lung function decline or compare the efficacy of different airway clearance techniques it employs. Without a robust data infrastructure, opportunities to improve protocols or catch worrying trends early can be missed.

Longitudinal Visibility

CF is a lifelong disease, but care is usually segmented by visits and acute issues. Providers may struggle to gain a longitudinal view of a patient's journey [7]. It can be challenging to easily answer questions like, "Has this patient's FEV_1 decline slowed since starting the new therapy last year?" or "What is our three-year outcome for patients who transitioned from pediatric to adult clinic?" Current electronic health records (EHRs) are not optimized for generating such longitudinal insights across a patient population. Thus, care teams may be reactive – addressing problems as they arise – rather than using data to be proactive in preventing complications.

Variable Adoption of Best Practices

With over 130 CF centers in the U.S. (and many more globally), not all centers achieve equal outcomes [1,7]. Some clinics excel in keeping patients' lung function high or infection rates low, but these successes may not be broadly shared or replicated. The current model relies on periodic conferences, publications, or CF Foundation updates for dissemination of best practices, which can lag behind real-time needs. Frontline clinicians lack a direct, continuous channel to learn what's working best elsewhere in today's patient population.

Resource and Workflow Constraints

Implementing new data collection or quality improvement initiatives can be burdensome [10]. Busy CF teams (physicians, nurses, respiratory therapists, dietitians, etc.) have limited time beyond direct patient care.

Without streamlined tools, they cannot feasibly track extra outcomes or conduct complex analyses in-house. Important aspects like patient-reported outcomes (symptoms, adherence, quality of life between visits) often go uncaptured because there isn't an easy, integrated way to do so during routine care. This means the full picture of patient health and treatment impact is not seen.

Collaboration Gaps

CF care improvements have historically been propelled by collaboration – for example, multi-center studies and the CF Foundation's network [1]. But day-to-day, individual providers are somewhat isolated in their practice, especially if they are not part of a major academic center. There is currently no simple mechanism for a group of CF clinicians to work together on a focused project (say, improving sinus disease management or sharing data on a new inhaled therapy) outside of formal research consortia. This limits the speed of innovation, as many great ideas stay local or anecdotal.

In summary, the current care model leaves a data and collaboration gap. Clinics excel at delivering care, but they often lack real-time learning systems to continuously improve that care. As patients live longer and new therapies emerge, this limitation becomes more pressing. Both patients and payers are increasingly outcome-focused: families want to know the likely benefits of starting a modulator at age 6, or the expected outcome after a certain intervention, and insurers scrutinize treatments for value [8,9]. Yet without high-quality data collected in routine practice, answering these questions with confidence is difficult. The next section explores this data and collaboration gap in more detail and sets the stage for how RegenMed Circles can help bridge it [10].

THE DATA AND COLLABORATION GAP IN CF

Despite CF being a data-aware field (thanks to things like the CF patient registry), significant gaps remain in how data is used to drive care improvements and research on a continuous basis [1,6]. The CF Registry aggregates outcomes from centers to provide annual reports and support large-scale studies, but it was not designed for real-time, granular feedback at the clinic level [1]. Moreover, some types of valuable data aren't captured uniformly in registries or EHRs – such as detailed treatment adherence information, symptom fluctuations between clinic visits, or patient satisfaction and daily functioning [6,7]. This creates a situation where clinicians are flying partially blind: they make decisions based on clinical experience and periodic data reviews, but lack a daily dashboard of how their interventions are performing across all their patients.

Key aspects of the data and collaboration gap include:

Real-Time Insights

A physician might wonder, "Across my clinic's CF population, did the introduction of Trikafta reduce pulmonary exacerbations this year compared to last?" or "How do our patients' lung function trajectories over the past 5 years compare to national averages?" Currently, answering such questions can take months of data wrangling or waiting for external reports. There is no instantaneous feedback loop [6,7]. This lag means missed opportunities to adjust treatments quickly or identify success stories to emulate.

Data Silos and Compatibility

Every CF center keeps records, but often in disparate systems or formats. If one center uses a custom database for tracking home spirometry readings and another uses only the hospital EHR, combining their insights is cumbersome. There is a lack of standardization and interoperability in how CF outcomes are recorded outside of the required registry fields [7]. This makes broad collaboration difficult – you can't easily pool data or compare notes if everyone speaks a different data "language." A lot of potentially useful information remains locked in free-text clinic notes or local spreadsheets.

Multicenter Collaboration Barriers

When clinicians do attempt to collaborate, they face logistical hurdles. For example, a few centers might want to compare their approaches to managing nontuberculous mycobacteria (NTM) lung infections in CF. Without a formal study, it's hard to share patient-level data due to privacy concerns and lack of a common platform [6,10]. Even de-identified data sharing can stall on questions of format, IRB approvals, or simply the lack of an easy-to-use tool. Thus, learning from each other's data is far from frictionless.

Longitudinal Research and RWE Needs

The success of CFTR modulators has created new research questions that traditional randomized trials may not fully answer [5,6]. For instance, what are the long-term outcomes of starting modulators in early childhood? Are there subpopulations who plateau or decline despite therapy, and why? Answering these requires observational real-world studies following patients over years. The CF field needs efficient ways to conduct such longitudinal research using data from routine care, without always resorting to lengthy prospective trials. In fact, regulatory agencies and the CF research community are increasingly looking to real-world evidence as a supplement to clinical trials – especially to study those patients who cannot take modulators or to evaluate new therapies on top of standard care [8,9]. But harnessing RWE requires high-quality, well-organized data from the clinical setting, which many centers struggle to compile.

Patient Engagement and Decentralized Data

Modern technology (apps, connected devices) offers new data streams – for example, home monitoring of lung function or patient-reported symptom scores via smartphone. These data could enrich understanding of CF in between clinic visits, but currently they often exist outside the medical record or in separate silos [6]. Integrating these patient-generated data into a cohesive picture, and doing so across many patients, is an unmet need. It also represents a missed chance for patients to contribute to and benefit from a collective knowledge network.

In essence, while the CF community has pockets of excellent data (e.g. the central registry and clinical trial results), the day-to-day practice environment has not caught up in terms of data-driven collaboration. There is a gap between potential and reality – we have the potential to learn from every patient's experience, but the reality is that most of that learning is lost or delayed. Bridging this gap requires a new infrastructure that can be embedded into care delivery itself, enabling real-time data capture, analysis, and secure sharing. RegenMed Circles for CF is built to provide that infrastructure, empowering clinicians with actionable data and a collaborative network without adding burden to their already busy workflows [10].

REGENMED CIRCLES FOR CF: A PLATFORM FOR COLLABORATIVE CARE

RegenMed Circles for CF are secure, collaborative networks that enable CF clinics and care teams to transform how they use data, all within the flow of routine care. Each Circle is a physician-led community focused on collecting and sharing real-world evidence in a specific area of interest, underpinned by a robust technology platform. By joining a CF Circle, centers gain access to a suite of tools and benefits designed to overcome the limitations discussed above. In particular, RegenMed Circles allow clinicians to:

Collect and Structure Real-World Treatment Outcomes with Zero Workflow Disruption

The platform integrates with existing clinic processes (and EHR systems where possible) to automatically capture key data points at each patient encounter. Lung function results, culture findings, treatment plans, and other outcomes can be recorded in standardized formats without extra data entry burdens. Even patient-reported outcomes or home monitoring data can be fed into the system via secure patient apps or portals. This means every clinic visit or patient interaction contributes to a growing, organized dataset without clinicians having to lift a finger beyond their normal documentation [10].

Compare Anonymized Results with Benchmarks and Peers

A core feature of Circles is the ability to view your center's performance in context. Data from all participating sites is aggregated (with strict de-identification and privacy safeguards) to generate blinded benchmarks. For example, a center can see how its average FEV_1 % predicted in adult patients compares to the national median in the Circle, or how its yearly pulmonary exacerbation rate stacks up against similar clinics. These insights are delivered through intuitive dashboards. Benchmarking in real-time helps identify where a clinic is excelling or where there is room for improvement, sparking quality improvement initiatives grounded in evidence [10].

Collaborate with Peers on Protocols, Research, and Publications

Within each Circle, clinicians can form a true learning community. The platform includes collaboration tools that allow discussion of results, sharing of protocols, and joint analysis of the data. If one site notices an interesting trend (e.g., an unusually effective inhaled therapy regimen), they can alert others and even co-design a study to explore it further. Circle members might co-author abstracts or papers using the pooled data, accelerating the dissemination of new insights. Importantly, Circles are physician-led – participants decide what questions to ask and what data to examine, making it a grassroots approach to multi-center research. This fosters a sense of ownership and active engagement in collective problem-solving [10].

Maintain Full Ownership and Control of their Data

RegenMed Circles is built on a principle of data sovereignty for contributors. Each clinic retains ownership of its own patient data and can opt in to any data-sharing or licensing arrangements. All shared data is de-identified and pooled only with consent. The platform is compliant with HIPAA and other relevant regulations, ensuring that patient privacy is paramount. Clinics never have to surrender their raw data to a third party; instead, they contribute to the Circle's aggregated insights while controlling how their information is used. This addresses a common concern when collaborating on data – with Circles, you get the benefits of a combined dataset without losing autonomy or risking confidentiality [10].

Each Circle in the CF domain focuses on a specific clinical or research theme to ensure that comparisons are apples-to-apples and discussions are targeted. For example, a few potential CF Circles could include:

- ***Modulator Outcomes Circle:*** Tracking and comparing long-term outcomes of patients on CFTR modulators. Centers in this Circle might focus on metrics like lung function trajectories before and after modulator initiation, exacerbation rates in modulator-treated patients, and side effect profiles (e.g. liver function changes, weight gain) across large cohorts [3,4,5]. The community could collaboratively develop best practices for monitoring and managing patients on these therapies.

- ***Infection Management Circle:*** Focusing on chronic infection outcomes, this Circle could aggregate data on sputum culture results, antibiotic use, and infection-related hospitalizations. Participants might compare approaches to suppressing Pseudomonas aeruginosa, eradication of Staphylococcus aureus or NTM, and outcomes of newer therapies (like phage therapy or inhaled nitric oxide in trial settings). By sharing data, clinicians could learn which infection control strategies correlate with better lung function preservation [2,6].

- ***Advanced CF and Transplant Circle:*** Centers with patients approaching advanced lung disease or post-transplant can collaborate on outcomes and care strategies. This might include tracking time to lung transplant referral, success rates of non-invasive ventilation or other bridging therapies, and post-transplant survival and complications. Such a Circle helps define benchmarks for end-stage CF care and supports knowledge exchange on when and how to transition patients to transplant or palliative care [6].

- ***CF Co-morbidities and Wellness Circle:*** As CF patients age, managing diabetes, liver disease, bone health, and mental health becomes vital. In this Circle, clinics could collect data on screening and outcomes for CF-related diabetes control (e.g., HbA1c levels, utilization of insulin pumps), liver

function trends and interventions, prevalence of anxiety/depression and use of mental health resources, etc. Comparing these data helps identify gaps in comprehensive care and effective models for treating these co-morbidities [6,7].

- ***Pediatric to Adult Transition Circle:*** This Circle could examine outcomes around the critical transition period when adolescent patients move to adult CF care. Metrics might include retention in care, changes in lung function or adherence during transition, and success of different transition support programs. By pooling experiences, CF teams can find the best ways to ensure continuity and avoid setbacks as young adults assume more responsibility for their care [6].

These are just a few examples – new Circles can be proposed by participating physicians based on emerging interests (for instance, a gene therapy outcomes Circle in the future, or a CF fertility/pregnancy Circle given the increasing family planning among CF patients) [7]. The flexibility of the platform means that if a group of clinicians has a question or a novel therapy to evaluate, a Circle can be created around that topic, complete with customized data capture forms and analytics.

USE CASES AND KEY OUTCOMES IN CF CIRCLES

What kinds of concrete questions and outcomes can RegenMed Circles help CF providers address? Below are several use cases and outcome types that illustrate how Circles turn data into actionable knowledge:

Assessing Treatment Impact

For any major therapy change, a Circle can quantify its impact. Example: Track FEV_1 % predicted change over 2 years in patients who started Trikafta, compared to similar patients prior to modulator availability [4,6]. Outcome measures might include the mean annual rate of lung function decline, which could reveal whether the therapy truly stabilizes disease progression in real-world settings. If one center's data shows an especially marked improvement, others can investigate what differences in care (earlier start, dosing adherence, etc.) might be contributing factors.

USE CASES AND KEY OUTCOMES IN CF CIRCLES

Optimizing Therapy Burden

CF care traditionally involves multiple daily treatments. Circles enable analysis of treatment regimens and outcomes to find the right balance. Example: Examine cohorts of patients who discontinued nebulized hypertonic saline or reduced airway clearance frequency after starting a modulator. Key outcomes could be pulmonary exacerbation frequency and quality-of-life scores (e.g., CFQ-R respiratory domain) in those who streamlined their routine versus those who kept the standard regimen [6]. If data indicates no decline in outcomes with a lighter regimen, it could inform guidelines to reduce patient burden safely.

Personalizing Infection Control

Use Circle data to determine which practices best prevent chronic infections. Example: Compare chronic Pseudomonas infection rates between centers using different eradication protocols when Pseudomonas is first detected. Outcomes like successful eradication at 12 months or time until chronic colonization can be tracked [6]. Another use case: monitoring antibiotic resistance patterns across centers to spot emerging trends early – e.g., rising incidence of multi-drug-resistant organisms – allowing the community to proactively adjust antibiotic policies or explore new treatments.

Monitoring Co-morbidities and Side Effects

With modulators and aging, tracking co-morbid health outcomes is crucial. Example: Follow BMI and nutritional status trends among adult patients on modulators. Are there instances of obesity or overweight developing? If so, do those correlate with certain demographic or treatment factors? Similarly, Circles can track CF-related diabetes incidence in the modulator era: Are fewer young patients developing diabetes due to better overall health, or is it unchanged? Outcome metrics like median age of onset of CFRD (CF-related diabetes) or proportion of patients with HbA1c >7% can be compared year over year [5,7]. This helps identify if new issues are arising that need guidelines updates (for instance, earlier glucose screening).

Evaluating Patient Engagement and Adherence

By integrating patient-reported data, Circles can study how engagement affects outcomes. Example: Collect patient-reported adherence data (perhaps via a mobile app where patients log treatments) and examine its correlation with health outcomes. A Circle could reveal, for instance, that patients who self-report at least 80% adherence to their airway clearance have 20% fewer exacerbations. Such evidence can make the case for investing in adherence programs or digital tools. Likewise, tracking patient satisfaction or quality of life alongside clinical metrics can show the value of certain interventions (e.g., does starting a mental health counseling program in a clinic improve patients' reported well-being?) [7,10].

USE CASES AND KEY OUTCOMES IN CF CIRCLES

Quality Improvement and Benchmarking

Each center can use Circle data internally to drive QI cycles. Example: If a clinic sees from the Circle dashboard that its annual hospitalization rate per patient is higher than the Circle average, it can drill down into its data. Perhaps pulmonary exacerbations are not being treated aggressively enough or there's a delay in IV antibiotic initiation. The team can implement a change (like a new exacerbation protocol) and then use the Circle's continuous data feed to monitor improvement in near-real time, rather than waiting for the next year's summary [10]. This turns the clinic's own practice into a learning health system, continually benchmarking against peers and striving for excellence.

In all these use cases, the key outcomes tracked typically include lung function (FEV_1 percent predicted), pulmonary exacerbation frequency, hospitalizations, use of IV antibiotics, BMI/nutritional status, infection status (like culture results for key pathogens), transplant referrals, survival rates, and patient-reported outcomes (symptoms, quality of life). Circles allow these outcomes to be filtered and viewed by subgroup (by genotype, by therapy, by age group, etc.), which is immensely powerful in a disease as heterogeneous as CF. By harnessing these data, CF providers can move from anecdotal decision-making to evidence-backed practices tailored to their patient population. For example, participants can see trend graphs of FEV_1 improvements for each patient plotted against a predicted average, or bar charts comparing exacerbation rates before and after a therapy change [5,6,10].





IMPROVING PATIENT OUTCOMES THROUGH REAL-WORLD EVIDENCE

The ultimate goal of RegenMed Circles for CF is to improve patient outcomes by learning from real-world evidence [7,10]. When CF clinics collectively harness data, several beneficial impacts on patient care emerge:

- **Identify and Spread Best Practices:** Real-world data can highlight which treatment protocols or management strategies are yielding the best results. If one center's data shows significantly slower lung function decline, the Circle can investigate and uncover the practice patterns behind that success (for instance, more aggressive early nutritional support or a unique adherence program) [7,10]. Those insights can then be shared and adopted by others, effectively raising the standard of care across all centers. Without RWE, such best-practice discovery is often delayed or missed entirely [8,9].

- **Refine Treatment Plans Continuously:** Instead of waiting for large trials or guidelines, clinicians can use Circle data to fine-tune treatments in near real time. For example, if data indicates that patients on a certain modulator are experiencing more frequent pulmonary exacerbations than expected, clinicians can respond by adding supportive therapies or closer monitoring. Conversely, if outcomes are excellent, they might safely de-escalate some therapies. This creates a feedback loop where treatment plans are constantly optimized based on evidence, leading to better health stability for patients [6,7,10].

- **Enhance Preventative Care:** Longitudinal tracking makes it possible to catch subtle declines or risk factors early. A slight downward trend in a patient's FEV_1 over a few months, flagged by the system, might prompt an earlier intervention (like a respiratory tune-up or addressing adherence issues) before a full-blown exacerbation occurs [7,10]. Similarly, if a Circle's combined data shows an uptick in a certain complication (say, rising hemoptysis rates in young adults), centers can proactively develop preventative strategies. Early intervention and preventative strategies mean patients avoid serious events and maintain higher quality of life [5].

- **Empower Patients with Data-Driven Care:** When clinics have robust evidence for their decisions, they can better educate and involve patients in care choices. For instance, a physician can confidently say, "Data from dozens of CF centers shows that starting this therapy now can improve your expected lung function by X% over the next year[5,7]." Showing a patient their personal health trajectory compared to peers (in a privacy-respecting way) can motivate adherence and engagement. In this way, RWE doesn't just guide clinicians – it also empowers patients and families, making care more transparent and personalized [6,10].

- **Extend Care Beyond Clinic Walls:** By incorporating real-world data, including patient-reported outcomes, Circles help bridge the gap between clinic visits [7,10]. Providers gain insight into how patients are doing at home, allowing for interventions like telehealth check-ins or adjustments to treatment plans in between scheduled visits. This means patient support becomes more continuous. Over time, such an approach can reduce emergency visits or hospitalizations, as issues are caught and addressed earlier [10]. Ultimately, this improves both patient outcomes and experience, as care becomes more responsive to real-life needs.

- **Drive Guideline Evolution and Precision Medicine:** As evidence accrues in Circles, it can inform updates to clinical guidelines and lead toward more precision medicine in CF [7,8,10]. For example, data might reveal that patients with certain rare mutations respond uniquely to a therapy, suggesting a tailored approach for that subset. Or it may show that an existing guideline (like quarterly clinic visits) could be modified for some patients (perhaps those very stable on modulators might safely do triannual visits with remote monitoring, whereas others need even more frequent follow-up). By grounding such changes in real-world evidence, we ensure that guidelines remain relevant and evidence-based in the face of evolving patient demographics and therapies [8,9].

From the clinic perspective, these improvements come without requiring additional full-time staff or complex IT projects. RegenMed Circles provides the heavy-lift of data aggregation and analysis, freeing clinicians to focus on interpreting and acting on the insights. The platform delivers interactive dashboards and cohort reports that distill the data into intuitive visuals and key performance indicators. Each participating site essentially gains a "virtual data scientist" in the background, continually analyzing their outcomes [10]. This level of analytics was once only available to large academic centers or through months-long research studies; Circles democratize it, making advanced insights available to any participating CF care program. In turn, this empowers even smaller or resource-constrained clinics to punch above their weight in delivering top-tier outcomes [10].

Most importantly, when real-world evidence is systematically applied, every patient stands to benefit. Treatments improve faster, care is more consistent, and fewer patients fall through the cracks. In a disease like CF – where every percentage point of lung function matters and every year of life gained is precious – this can translate into tangible improvements in survival and well-being community-wide [5,7].

RESEARCH AND REVENUE BENEFITS FOR CF CENTERS

Beyond clinical care improvements, RegenMed Circles for CF offers significant research and financial benefits for participating centers. In today's healthcare environment, finding sustainable ways to fund innovation and reward quality is crucial. Circles create a model where doing the right thing for patients can also bolster a center's research profile and revenue stream:

RESEARCH AND REVENUE BENEFITS FOR CF CENTERS

- **Accelerate Clinical Research:** The aggregated, standardized data from Circles is a treasure trove for clinical research and hypothesis generation. Centers can leverage the data to conduct observational studies or to plan interventional trials [10]. For example, with Circle data one could quickly assemble a cohort of patients meeting certain criteria (say, F508del homozygous teens pre-modulator) and analyze outcomes, which might inform a grant proposal or a new study. Being part of a Circle also makes multi-center studies far easier to execute, since the data infrastructure and collaboration network are already in place [10]. Many RegenMed Circle members go on to co-author scientific publications and conference presentations, showcasing their findings. This elevates the profile of the institution and physicians as leaders in CF research [7]. Participation in such cutting-edge research can also be a draw for patients who want access to the latest advancements [5].

- **Contribute to Regulatory-Grade RWE:** As mentioned earlier, regulatory bodies are looking to real-world evidence to support new drug approvals or label expansions in CF (for instance, to approve therapies for rare mutations or to understand long-term safety of modulators) [8,9]. Data collected through Circles can potentially be used (in collaboration with bodies like the CF Therapeutics Development Network) to provide RWE for regulatory submissions [8]. Centers that contribute to this effort are directly impacting the future therapeutic landscape – helping bring new treatments to patients faster. This kind of contribution is intellectually rewarding and establishes the center as a key stakeholder in the CF innovation ecosystem [7].

- **Monetize De-identified Data Responsibly:** RegenMed Circles provides a pathway for centers to license their de-identified, aggregate data to interested industry partners (pharmaceutical companies, biotech, medical device firms, or digital health companies) in a compliant and ethical manner [10]. CF is a prime area of industry interest, with companies keen to understand real-world usage of their drugs (like modulators), outcomes in diverse patient populations, and areas of unmet need for new product development [6,10]. By contributing data to a Circle, a clinic can partake in data licensing opportunities negotiated by RegenMed or the Circle consortium. The revenue from such licenses flows back to the contributing sites, with up to 85% of licensing fees returning to the clinics. This can translate into hundreds of thousands of dollars in new revenue for a busy CF center over time – funds that can be reinvested in patient care, research personnel, or facility improvements [10].

- **Attract Biotech and Pharma Partnerships:** Centers with robust real-world data capabilities become attractive partners for clinical trials and sponsored research [10]. Pharma companies often seek out sites that can quickly identify eligible patients for trials or that have a track record of high-quality data management. By advertising involvement in a CF Circle, a center signals that it is at the forefront of data-driven care. This can lead to invitations to participate in Phase IV studies (post-marketing studies of modulators, for example), grants from foundations or industry to explore specific questions, or pilot programs with new technologies (like a company testing a home monitoring device in CF) [10].

:h partnerships not only come with funding but also give the center early access to innovative interventions [10].

- **Support Quality Incentives and Value-Based Care:** There is a broader trend in healthcare toward value-based reimbursement, where providers might be rewarded for keeping patients healthier and reducing costly interventions [9,10]. Having concrete data on outcomes is essential to succeed in these models. A CF Circle equips centers with precisely the evidence needed to demonstrate value – e.g., if a payer or health system asks for proof that a clinic's CF care has reduced hospital days or improved functional status, the data is readily available [10]. Centers can thus negotiate better support or incentives with payers by showcasing their outcomes. In some cases, consortium data might be used to develop new standards for value-based agreements in rare diseases like CF [10].

- **Professional Development and Recognition:** Being part of a Circle connects clinicians with a network of like-minded professionals, opening the door to mentorship, speaking opportunities, and leadership roles. For instance, a physician who spearheads a particular Circle project may be invited to present at the North American Cystic Fibrosis Conference (NACFC) or join a guideline committee because of their data insights. The reputation boost for both individual providers and their institutions can lead to increased patient referrals (families often seek out centers known for innovation) and prestige. In a competitive healthcare market, branding a CF program as a "Center of Excellence in Data-Driven Care" can differentiate it significantly.

RegenMed handles all data licensing agreements, compliance checks, and partner negotiations, so that clinicians can focus on medicine and science rather than contracts. Importantly, any data sharing with third parties is aggregate-only and de-identified, ensuring patient privacy is never compromised [10]. Revenue generation through Circles is designed to be transparent and aligned with clinical values – meaning we prioritize partnerships that will ultimately benefit patients (for example, funding new research or improving care delivery) while compensating centers fairly for the insights their data provides [10].

In summary, Circles create a win-win scenario: the more a center contributes and improves its care (through data-driven learning), the more opportunities it gains to earn revenue and contribute to groundbreaking research. This sustainable model helps justify the time and effort clinicians put into data initiatives by delivering tangible returns to their practice. It transforms what was once seen as pure "overhead" (data entry, tracking outcomes) into a valuable asset and a source of funding for further innovation [10].

CALL TO ACTION

Cystic fibrosis care stands at a pivotal moment. The achievements of the past decades are remarkable – we have turned a once-fatal disease into one where a child born today with CF can realistically hope to live into middle age and beyond [2,5]. But with this progress comes the responsibility to push further: to ensure every patient, regardless of their mutation or circumstances, benefits from the latest knowledge; to fine-tune therapies so that quality of life is as important a goal as quantity of life; and ultimately, to find a cure or functional cure for all [6,7]. Achieving these goals will require the CF community to work smarter and more collaboratively than ever before. RegenMed Circles for CF offer a powerful means to do exactly that [10].

By joining a Circle, your clinic becomes part of a forward-looking network of CF innovators who are determined to make every data point count. Whether you are focused on optimizing the use of CFTR modulators, tackling stubborn challenges like chronic infections, or preparing for the era of gene therapies, Circles turn your everyday clinical practice into a continuous learning and improvement engine [10]. You and your peers will be able to see the impact of interventions in real time, learn from each other on a secure platform, and collectively set new standards of care. This is patient-centric innovation at its best: when clinicians unite around data for the sake of better patient outcomes, everybody wins [10].

We invite CF care centers, clinicians, and researchers to embrace this new model of collaborative care and research. Joining a RegenMed Circle is straightforward and tailored to your needs. Our team will work with you to identify the outcomes you care about most, integrate the platform with your workflow, and ensure you start gaining insights quickly. From there, the possibilities are vast: contribute to multi-center studies, co-create new knowledge, and even generate revenue that can be funneled back into your program [10]. You remain in full control of your participation and data at all times – what you share and with whom is up to you and your Circle community.

Now is the time to act. The CF field is moving faster than ever, and the decisions we make in this modulator era will shape patient lives for decades. Don't let your clinic operate in isolation or let valuable information slip through the cracks. Become a part of a CF Circle and amplify your impact [10]. Together, by leveraging real-world evidence and community insight, we can ensure that improvements in CF care not only continue but accelerate – reaching every patient and setting new benchmarks for what is possible.

Join a growing network of physician-led innovators who are shaping the future of cystic fibrosis care with real-world data. Let's make sure that every breakthrough, every success in one clinic, can be shared and built upon by all [10].

Visit **www.rgnmed.com/circles** or contact us at **circles@rgnmed.com** to learn how to join or launch your own Cystic Fibrosis Circle today. Together, we will elevate CF care to new heights and forge the next chapter in the fight against cystic fibrosis.

References

1. Cystic Fibrosis Foundation. (2023). Patient Registry Annual Data Report. https://www.cff.org
2. Rowe SM, Miller S, Sorscher EJ. (2005). Cystic fibrosis. New England Journal of Medicine, 352(19), 1992–2001.
3. Ramsey BW, et al. (2011). A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. NEJM, 365(18), 1663–1672.
4. Heijerman HGM, et al. (2019). Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single Phe508del allele. NEJM, 381(19), 1809–1819.
5. Bell SC, et al. (2020). The future of cystic fibrosis care: a global perspective. Lancet Respiratory Medicine, 8(1), 65–124.
6. Taylor-Cousar JL, et al. (2021). CFTR modulators: impact on long-term health outcomes. Journal of Cystic Fibrosis, 20(4), 565–574.
7. Zemanick ET, et al. (2023). Real-world data and the next frontier in CF care. Chest, 163(1), 12–22.
8. European Medicines Agency. (2023). Real-world evidence in regulatory decision-making. https://www.ema.europa.eu
9. U.S. Food and Drug Administration. (2021). Framework for FDA's Real-World Evidence Program. https://www.fda.gov
10. RegenMed Circles Internal Data and Platform Overview, 2024.